Drug Approval | March 19, 2024
Sun Pharmaceuticals receives approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
WINLEVI works differently from any other topical acne treatment
Subscribe To Our Newsletter & Stay Updated
